Compare NRO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRO | TLSA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.2M | 155.3M |
| IPO Year | 2003 | 2017 |
| Metric | NRO | TLSA |
|---|---|---|
| Price | $2.93 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 208.7K | ★ 215.1K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.74 | $1.04 |
| 52 Week High | $3.37 | $2.60 |
| Indicator | NRO | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.88 | 38.00 |
| Support Level | $2.92 | $1.11 |
| Resistance Level | $3.09 | $1.44 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 29.41 | 29.17 |
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.